Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28

Vaccine

Volumn 28, Issue 35, 2010, Pages 5691-5702

  Kahl, Christoph A ^a,b   Bonnell, Jessica ^a   Hiriyanna, Suja ^a   Fultz, Megan ^a   Nyberg Hoffman, Cassandra ^a   Chen, Ping ^a   King, C Richter ^a,c   Gall, Jason G D ^a  

^a GENVEC INC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

Adenovirus; Human vaccine; Seroprevalence; Vector

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; MEMBRANE COFACTOR PROTEIN; VACCINE; VIRUS VACCINE;

ADENOVIRUS 5; ANTIBODY RESPONSE; ARTICLE; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SEROPREVALENCE; T LYMPHOCYTE; TRANSGENE; UNITED STATES; ADOLESCENT; ADULT; AGED; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CELL LINE; CELLULAR IMMUNITY; EPIDEMIOLOGY; FEMALE; GENE VECTOR; HUMAN ADENOVIRUS; IMMUNOLOGY; MALE; MIDDLE AGED; MONONUCLEAR CELL; MOUSE; SERODIAGNOSIS; YOUNG ADULT;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD46; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES; VIRAL VACCINES; YOUNG ADULT;

EID: 77955089091     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.050     Document Type: Article

References (63)

1. Barouch D.H., Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005, 16(February (2)):149-156.
2. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 2004, 10(October (4)):616-629.
3. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77(June (11)):6305-6313.
4. Prevec L, Campbell J.B., Christie B.S., Belbeck L., Graham F.L. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990, 161(January (1)):27-30.
5. He Z., Wlazlo A.P., Kowalczyk D.W., Cheng J., Xiang Z.Q., Giles-Davis W., et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000, 270(April (1)):146-161.
6. Xiang Z.Q., Yang Y., Wilson J.M., Ertl H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996, 219(1):220-227.
7. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(February (4)):1959-1964.
8. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367(February (9509)):475-481.
9. Casimiro D.R., Tang A., Chen L., Fu T.M., Evans R.K., Davies M.E., et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77(July (13)):7663-7668.
10. Letvin N.L., Huang Y., Chakrabarti B.K., Xu L., Searman M.S., Beaudry K., et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004, 78(July (14)):7490-7497.
11. Gilbert S.C., Schneider J., Hannan C.M., Hu J.T., Plebanski M., Sinden R., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002, 20(January (7-8)):1039-1045.
12. Rodrigues E.G., Claassen J., Lee S., Wilson J.M., Nussenzweig R.S., Tsuji M. Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 2000, 22(March (3)):157-160.
13. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998, 177(May (5)):1155-1161.
14. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170(February (3)):1416-1422.
15. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., Kostense S., Penders G., Helmus N., Koudstaal W., Cecchini M., Wetterwald A., Sprangers M., Lemckert A., Ophorst O., Koel B., van Meerendonk M., Quax P., Panitti L., Grimbergen J., Bout A., Goudsmit J., Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77(August (15)):8263-8271.
16. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007, 81(May (9)):4654-4663.
17. Seshidhar Reddy P., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., Kaleko M., Connelly S. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311(July (2)):384-393.
18. Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004, 55:355-372.
19. Fattori E., Zampaglione I., Arcuri M., Meola A., Ercole B.B., Cirillo A., et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther 2006, 13(July (14)):1088-1096.
20. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002, 76(March (6)):2667-2675.
21. Hensley S.E, Cun A.S., Giles-Davis W., Li Y., Xiang Z., Lasaro M.O., et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 2007, 15(February (2)):393-403.
22. Sridhar S., Reyes-Sandoval A., Draper S.J., Moore A.C., Gilbert S.C., Gao G.P., et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 2008, 82(April (8)):3822-3833.
23. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008, 38(March (3)):732-741.
24. Philpott N.J., Nociari M., Elkon K.B., Falck-Pedersen E. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci USA 2004, 101(April (16)):6200-6205.
25. Liu Q., Muruve D.A. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003, 10(June (11)):935-940.
26. Iacobelli-Martinez M., Nemerow G.R. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J Virol 2007, 81(February (3)):1305-1312.
27. Iacobelli-Martinez M., Nepomuceno R.R., Connolly J., Nemerow G.R. CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines. J Virol 2005, 79(September (17)):11259-11268.
28. Muruve D.A., Petrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452(March (7183)):103-107.
29. Nociari M., Ocheretina O., Schoggins J.W., Falck-Pedersen E. Sensing infection by adenovirus: toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol 2007, 81(April (8)):4145-4157.
30. Brough D.E., Lizonova A., Hsu C., Kulesa V.A., Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996, 70(September (9)):6497-6501.
31. Brough D.E., Lizonova A., Hsu C., Kulesa V.A., Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996, 70(9):6497-6501.
32. Lemiale F., Haddada H., Nabel G.J., Brough D.E., King C.R., Gall J.G. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 2007, 25(March (11)):2074-2084.
33. Hamilton M.M., Byrnes G.A., Gall J.G., Brough D.E., King C.R., Wei L.L. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis 2008, 14:2535-2546.
34. Cleghon V., Piderit A., Brough D.E., Klessig D.F. Phosphorylation of the adenovirus DNA-binding protein and epitope mapping of monoclonal antibodies against it. Virology 1993, 197:564-575.
35. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996, 70(November (11)):7498-7509.
36. McVey D., Zuber M., Ettyreddy D., Brough D.E., Kovesdi I. Rapid construction of adenoviral vectors by lambda phage genetics. J Virol 2002, 76(April (8)):3670-3677.
37. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003, 41(November (11)):5046-5052.
38. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172(May (10)):6290-6297.
39. Hsu C., Boysen M., Gritton L.D., Frosst P.D., Nemerow G.R., Von Seggern D.J. In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity. Virology 2005, 332(February (1)):1-7.
40. Ophorst O.J., Kostense S., Goudsmit J., De Swart R.L., Verhaagh S., Zakhartchouk A., et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004, 22(August (23-24)):3035-3044.
41. Bergelson J., Cunningham J., Droguett G., Kurt-Jones E., Krithivas A., Hong J., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (New York, NY) 1997, 275(5304):1320-1323.
42. Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003, 9(November (11)):1408-1412.
43. Marttila M., Persson D., Gustafsson D., Liszewski M.K., Atkinson J.P., Wadell G., et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 2005, 79(November (22)):14429-14436.
44. Rosen L., Baron S., Bell J.A. Four newly recognized adenoviruses. Proc Soc Exp Biol Med 1961, 107(June):434-437.
45. Chen W., Anton L.C., Bennink J.R., Yewdell J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000, 12(January (1)):83-93.
46. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003, 77(January (1)):799-803.
47. Liu J., Ewald B.A., Lynch D.M., Denholtz M., Abbink P., Lemckert A.A., et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008, 82(May (10)):4844-4852.
48. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005, 79(August (15)):9694-9701.
49. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23(November (46-47)):5404-5410.
50. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(January (7225)):87-91.
51. Roelvink P.W., Lizonova A., Lee J.G., Li Y., Bergelson J.M., Finberg R.W., Brough D.E., Kovesdi I., Wickham T.J. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998, 72(10):7909-7915.
52. Arnberg N, Edlund K., Kidd A.H., Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000, 74(January (1)):42-48.
53. Arnberg N., Kidd A.H., Edlund K., Olfat F., Wadell G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J Virol 2000, 74(August (16)):7691-7693.
54. Wu E., Trauger S.A., Pache L., Mullen T.M., von Seggern D.J., Siuzdak G., et al. Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. J Virol 2004, 78(April (8)):3897-3905.
55. Persson B.D., Muller S., Reiter D.M., Schmitt B.B., Marttila M., Sumowski C.V., et al. An arginine switch in the species B adenovirus knob determines high-affinity engagement of the cellular receptor CD46. J Virol 2009, 83(January (2)):673-686.
56. Holers V.M., Kinoshita T., Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today 1992, 13(June (6)):231-236.
57. Kawai T., Akira S. Innate immune recognition of viral infection. Nat Immunol 2006, 7(February (2)):131-137.
58. Ishii K.J., Kawagoe T., Koyama S., Matsui K., Kumar H., Kawai T., et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451(February (7179)):725-729.
59. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434(April (7034)):772-777.
60. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004, 18(May (8)):1213-1216.
61. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006, 12(October (10)):1596-1599.
62. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(November (9653)):1881-1893.
63. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(November (9653)):1894-1905.